Two for the price of one: Antibody drugs work by binding to antigens such as extracellular proteins or receptors on a cell's surface, blocking their ability to function or targeting them for ...

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

Regeneron Pharmaceuticals’ monoclonal antibody treatment is making a difference in treating patients who have tested positive for COVID-19 or have recently been exposed to the virus. Now, we’re ...

A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

New antibody therapy stopped tumor growth and blocked spread in treatment-resistant triple-negative breast cancer models.

In its first bullet point in its release breaking down fourth quarter earnings, Regeneron said that sales of its coronavirus antibody treatment were $2.30 billion in the period, which represented a ...

The recent discovery of a novel antibody that works in an unusual way might inspire ideas for designing more effective vaccines. Among the common pathogens that could be targeted are urinary-tract ...

JACKSONVILLE, Fla. — A picture taken inside the downtown Jacksonville Regeneron antibody site at the library shows patients lying on the floor while waiting for treatment. Louis Lopez took the picture ...